French biotech raises €5m, looks to restore patient response to anticancer immunotherapies

EverImmune, a biotech based near Paris, and specialized in the development of live biotherapeutic products in the field of microbiota oncology, has raised €5m (US$5.7m) in a Series A funding round from undisclosed private investors.

Related Keywords

France ,Belgium ,French ,Romain Daillere ,Gustave Roussy ,Jean Luc Marsat ,Laurence Zitvogel ,Jules Bordet Institute ,Dijon Bourgogne University Hospital ,Prof Laurence Zitvogel ,Non Small Cell Lung Cancer ,Renal Cell Cancer ,Jules Bordet ,Bio Developments ,Pipelines ,Gut Microbiota ,Checkpoint Inhibitor ,Live Biotherapeutics ,